{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T07:24:19Z","timestamp":1793863459877,"version":"4.6.1"},"reference-count":109,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T00:00:00Z","timestamp":1574640000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:p>The development of chimeric antigen receptor (CAR) T\u2010cell therapy for select hematological malignancies represents one of the most remarkable therapeutic advances in the past decade. Currently, CD19\u2010targeted CAR T\u2010cell therapy is approved for relapsed\/refractory diffuse large B\u2010cell lymphoma and acute lymphoblastic leukemia. However, there is significant interest in the application of CAR T\u2010cell therapy to other hematological malignancies, including multiple myeloma, where the current focus is on the development of B\u2010cell maturation antigen\u2010directed CAR T\u2010cell therapy. Despite the successes achieved to date, there remain significant challenges associated with CAR T\u2010cell therapy and substantial research efforts are underway to develop new targets and approaches. Here, we provide an overview of the rapidly evolving landscape of CAR T\u2010cell therapy in hematological malignancies and look ahead at the advances that will shape the future of this field.<\/jats:p>","DOI":"10.1002\/cpt.1674","type":"journal-article","created":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T13:04:12Z","timestamp":1571317452000},"page":"112-122","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":148,"title":["CAR T\u2010Cell Therapy in Hematologic Malignancies: A Voyage in Progress"],"prefix":"10.1111","volume":"107","author":[{"given":"Sarah A.","family":"Holstein","sequence":"first","affiliation":[{"name":"Division of Oncology and Hematology Department of Internal Medicine University of Nebraska Medical Center Omaha Nebraska USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew A.","family":"Lunning","sequence":"additional","affiliation":[{"name":"Division of Oncology and Hematology Department of Internal Medicine University of Nebraska Medical Center Omaha Nebraska USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,11,25]]},"reference":[{"key":"e_1_2_9_1_1","doi-asserted-by":"publisher","DOI":"10.3109\/00313029009063782"},{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.828354"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.5BT1215-556RR"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-013-1540-9"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705074"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.00.240"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni1001-957"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.24.10024"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.2.720"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-017-0102-y"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.181.5.1653"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.7505"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-769620"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.95"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3884"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30864-7"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-110747"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.04.051"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1042\/BST20150291"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1676"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0231"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2257"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1512503112"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2017.234"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2016.142"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.15218"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1300"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri2326"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI83092"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.4195"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0458"},{"key":"e_1_2_9_35_1","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1182\/blood.V130.Suppl_1.1547.1547","article-title":"Phase 1 results from ZUMA\u2010 6: axicabtagene Ciloleucel (axi\u2010cel; KTE\u2010C19) in combination with atezolizumab for the treatment of patients with refractory diffuse large B cell lymphoma (DLBCL)","volume":"130","author":"Locke F.L.","year":"2017","journal-title":"Blood"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.128_2629"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00767"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10060200"},{"key":"e_1_2_9_39_1","first-page":"71","article-title":"FDG\u2010PET for early response assessment in lymphomas: Part 2\u2010diffuse large B\u2010cell lymphoma, use of quantitative PET evaluation","volume":"31","author":"Cheson B.D.","year":"2017","journal-title":"Oncology (Williston Park)"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.6637"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-119335"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.138826"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.21.120601.141152"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-9822(00)00566-2"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-2422"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-2043"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI126397"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.77.8084"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817226"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0681-6"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-117729"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-112786"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-117964"},{"key":"e_1_2_9_54_1","first-page":"506","article-title":"Combined infusion of CD19 and Bcma\u2010specific chimeric antigen receptor T cells for RRMM: initial safety and efficacy report from a clinical pilot study","volume":"130","author":"Yan L.","year":"2017","journal-title":"Blood"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-114980"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-111419"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-118569"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-116953"},{"key":"e_1_2_9_59_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms8333"},{"key":"e_1_2_9_60_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0307"},{"key":"e_1_2_9_61_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-117974"},{"key":"e_1_2_9_62_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-119633"},{"key":"e_1_2_9_63_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2559"},{"key":"e_1_2_9_64_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0197349"},{"key":"e_1_2_9_65_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI86000"},{"key":"e_1_2_9_66_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau7746"},{"key":"e_1_2_9_67_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-04-778423"},{"key":"e_1_2_9_68_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.26792"},{"key":"e_1_2_9_69_1","first-page":"3142","article-title":"Chimeric antigen receptor (CAR) T cells specific for CD229: a potentially curative approach for multiple myeloma","volume":"130","author":"Venniyil Radhakrishnan S.","year":"2017","journal-title":"Blood"},{"key":"e_1_2_9_70_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4431"},{"key":"e_1_2_9_71_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-118580"},{"key":"e_1_2_9_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2019.04.001"},{"key":"e_1_2_9_73_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-116403"},{"key":"e_1_2_9_74_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2016.1.504"},{"key":"e_1_2_9_75_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0344"},{"key":"e_1_2_9_76_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.183475"},{"key":"e_1_2_9_77_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2018.08.008"},{"key":"e_1_2_9_78_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-7142-8_17"},{"key":"e_1_2_9_79_1","first-page":"1359","article-title":"Treating relapsed\/refractory (RR) AML with biodegradable anti\u2010CD123 CAR modified T cells","volume":"130","author":"Cummins K.D.","year":"2017","journal-title":"Blood"},{"key":"e_1_2_9_80_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V130.Suppl_1.811.811"},{"key":"e_1_2_9_81_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-110579"},{"key":"e_1_2_9_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.05.013"},{"key":"e_1_2_9_83_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.148"},{"key":"e_1_2_9_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"e_1_2_9_85_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-114093"},{"key":"e_1_2_9_86_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-112254"},{"key":"e_1_2_9_87_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-111711"},{"key":"e_1_2_9_88_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-117199"},{"key":"e_1_2_9_89_1","first-page":"20","article-title":"Building a program: implications for infrastructure, nursing education, and training for CAR T\u2010cell therapy","volume":"23","author":"Taylor L.","year":"2019","journal-title":"Clin. J. Oncol. Nurs."},{"key":"e_1_2_9_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.copbio.2018.01.025"},{"key":"e_1_2_9_91_1","doi-asserted-by":"publisher","DOI":"10.1002\/biot.201700095"},{"key":"e_1_2_9_92_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-018-2436-z"},{"key":"e_1_2_9_93_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-114527"},{"key":"e_1_2_9_94_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-113744"},{"key":"e_1_2_9_95_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-113731"},{"key":"e_1_2_9_96_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-119197"},{"key":"e_1_2_9_97_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-110194"},{"key":"e_1_2_9_98_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-110142"},{"key":"e_1_2_9_99_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-119650"},{"key":"e_1_2_9_100_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-117737"},{"key":"e_1_2_9_101_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-113163"},{"key":"e_1_2_9_102_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-111528"},{"key":"e_1_2_9_103_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-117694"},{"key":"e_1_2_9_104_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-114396"},{"key":"e_1_2_9_105_1","doi-asserted-by":"crossref","first-page":"7557","DOI":"10.1200\/JCO.2019.37.15_suppl.7557","article-title":"A phase I trial using CD19 CAR\u2010T expressing PD\u20101\/CD28 chimeric switch\u2010receptor for refractory or relapsed B\u2010cell lymphoma","volume":"37","author":"Liu H.","year":"2019","journal-title":"J. Clin. Oncol"},{"key":"e_1_2_9_106_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1819745116"},{"key":"e_1_2_9_107_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-116898"},{"key":"e_1_2_9_108_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-113220"},{"key":"e_1_2_9_109_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-113548"}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpt.1674","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.1674","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpt.1674","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.1674","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T08:36:36Z","timestamp":1699346196000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.1674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,25]]},"references-count":109,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["10.1002\/cpt.1674"],"URL":"https:\/\/doi.org\/10.1002\/cpt.1674","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,25]]},"assertion":[{"value":"2019-08-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-11-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}